Immunovant, Inc.
Immunovant, Inc. (IMVT) Net Income & Profit History
Annual & trailing net income, net margin, YoY change, and peer profitability context.
IMVT · net income · updated Jun 8, 2026
Core profitability metrics
IMVT · net income · margin · TTM · CAGRNet income was −$505.6M for FY2026 (fiscal year ending 2026-03-31), down 22.2% year-over-year. Net profit margin was —.
Annual net income history
▸ FMP /income-statement · Annual · IMVT net income history · IMVT profit margin
Annual net income data
Net income vs peers (Healthcare)
About Net Income & Methodology
Immunovant, Inc. (IMVT) reported net income of −$505.6M for FY2026 (fiscal year ending 2026-03-31), down 22.2% year-over-year. The net profit margin was — — meaning the company kept $— of every dollar of revenue as profit.
Immunovant, Inc. has not yet achieved annual profitability based on available data (9 fiscal years). The company has reported net losses across all available periods.
Immunovant, Inc.'s net profit margin was — for FY2026, based on the latest annual results.
Investors sometimes search for "Immunovant, Inc. net worth" — the company's market capitalization is a separate figure from IMVT net income. Data sourced from FMP /income-statement · US GAAP · USD.
Frequently asked questions
IMVT net income · 4 questionsImmunovant, Inc. is not currently profitable on an annual basis. The company reported a net loss of $505.6M for FY2026.
▸ Source: FMP /income-statement · GAAP · Immunovant, Inc. · Immunovant, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026